TY - JOUR
T1 - Disseminated mucormycosis in a patient with severe COVID-19 on venovenous extracorporeal membrane oxygenation
T2 - A case report
AU - Ito, Hazuki
AU - Kakizaki, Ryuichiro
AU - Harada, Keisuke
AU - Kyuno, Daisuke
AU - Kubo, Terufumi
AU - Bunya, Naofumi
AU - Kasai, Takehiko
AU - Uemura, Shuji
AU - Narimatsu, Eichi
N1 - Publisher Copyright:
© 2022
PY - 2022/1
Y1 - 2022/1
N2 - Background: Since the global outbreak of coronavirus disease 2019 (COVID-19), there have been several reports of mucormycosis as a secondary complication. However, the disseminated type of mucormycosis is extremely rare. Case: A 58-year-old male patient with COVID-19 started receiving venovenous extracorporeal membrane oxygenation because of severe respiratory failure. During hospitalization, intra-abdominal hemorrhage occurred and an emergency laparotomy was performed. Subsequently, the patient suffered septic shock, and part of the small intestines and the abdominal wall became necrotic. Finally, the patient died. At autopsy, he was diagnosed with disseminated mucormycosis. Conclusion: Disseminated mucormycosis should be considered in patients with COVID-19 with refractory sepsis unresponsive to broad-spectrum antimicrobial therapy.
AB - Background: Since the global outbreak of coronavirus disease 2019 (COVID-19), there have been several reports of mucormycosis as a secondary complication. However, the disseminated type of mucormycosis is extremely rare. Case: A 58-year-old male patient with COVID-19 started receiving venovenous extracorporeal membrane oxygenation because of severe respiratory failure. During hospitalization, intra-abdominal hemorrhage occurred and an emergency laparotomy was performed. Subsequently, the patient suffered septic shock, and part of the small intestines and the abdominal wall became necrotic. Finally, the patient died. At autopsy, he was diagnosed with disseminated mucormycosis. Conclusion: Disseminated mucormycosis should be considered in patients with COVID-19 with refractory sepsis unresponsive to broad-spectrum antimicrobial therapy.
KW - COVID-19 associated mucormycosis
KW - Invasive fungal infection
KW - Invasive mucormycosis
KW - Steroid
UR - http://www.scopus.com/inward/record.url?scp=85134802866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134802866&partnerID=8YFLogxK
U2 - 10.1016/j.idcr.2022.e01578
DO - 10.1016/j.idcr.2022.e01578
M3 - Article
AN - SCOPUS:85134802866
SN - 2214-2509
VL - 29
JO - IDCases
JF - IDCases
M1 - e01578
ER -